Gilead Sciences, Inc.

As of October 17, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued compared to its peers, with a P/E ratio of 15 and a significant underperformance in long-term returns relative to the S&P 500.

As of October 17, 2025, Gilead Sciences, Inc. is considered very expensive with overvaluation indicators despite strong performance, as its P/E ratio is lower than the peer average and its PEG ratio suggests premium pricing relative to peers.

As of September 19, 2025, Gilead Sciences, Inc. shows a bullish technical trend with mixed signals, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the last five years.

As of September 19, 2025, Gilead Sciences, Inc. is in a bullish trend, supported by positive daily moving averages and KST signals, though short-term indicators like the weekly MACD and OBV show mild bearishness, reflecting mixed signals despite strong year-to-date performance.

As of September 5, 2025, Gilead Sciences, Inc. shows a bullish trend overall, despite mixed signals from the MACD and OBV, with a year-to-date return of 23.01% compared to the S&P 500's 12.22%.

As of July 7, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued due to its lower P/E ratio compared to peers, despite strong profitability metrics and recent stock performance that has outpaced the S&P 500 year-to-date.

As of June 2, 2025, Gilead Sciences, Inc. shows a mildly bullish trend with daily moving averages indicating bullish momentum, but weekly indicators suggest caution due to mildly bearish MACD and KST, while the monthly outlook remains bullish despite a bearish RSI.

As of February 13, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued, with a P/E ratio of 15 compared to the industry average of 21.64, an EV to EBITDA ratio of 11.39, and recent stock performance lagging behind the S&P 500.

As of March 2022, Gilead Sciences, Inc.'s management team includes Chairman and CEO Daniel O'Day, Lead Independent Director Kevin Lofton, Directors Jeffrey Bluestone, Javier Rodriguez, Anthony Welters, and Independent Director Jacqueline Barton. They are responsible for the company's strategic direction and operations.

Gilead Sciences, Inc. is a large-cap biopharmaceutical company focused on discovering, developing, and commercializing medicines, with a net sales of $6.646 billion and a market cap of approximately $134.34 billion as of March 2025. Key financial metrics include a P/E ratio of 15.00 and a dividend yield of 2.89%.

As of Jun 18, Gilead Sciences, Inc. has a market capitalization of $134.34 billion, with net sales of $28.69 billion and a net profit of $5.97 billion over the latest four quarters. The company's total assets amount to $58.99 billion, with shareholder's funds of $19.33 billion.